Passage Bio Investor Relations Material

Passage Bio Inc. is a clinical-stage genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disorders. The company utilizes a proprietary gene therapy platform in collaboration with the University of Pennsylvania’s Gene Therapy Program to deliver adeno-associated virus (AAV)-based therapeutics directly to the CNS. Passage Bio’s pipeline includes treatments targeting conditions such as frontotemporal dementia, Krabbe disease, and other inherited neurodegenerative and neurodevelopmental disorders. The company is headquartered in Philadelphia, Pennsylvania, and its shares are listed on the NASDAQ.